We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRideā¢ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRideā¢, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types. LogicBio has been acquired by Alexion, AstraZeneca Rare Disease. For future updates on our genome editing program, follow Alexion Pharmaceuticals.
View Top Employees from LogicBio TherapeuticsWebsite | http://www.logicbio.com |
Ticker | LOGC |
Revenue | $7 million |
Funding | $49 million |
Employees | 21 (21 on RocketReach) |
Founded | 2014 |
Address | 65 Hayden Ave, Lexington, Massachusetts 02421, US |
Phone | (617) 245-0399 |
Technologies |
JavaScript,
HTML,
Twitter
+23 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Science and Engineering, Healthcare, Genetics, Health Care |
Competitors | Beam Therapeutics, Editas Medicine, Homology Medicines, Inc., Sigilon Therapeutics, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325414 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular LogicBio Therapeutics employee's phone or email?
The LogicBio Therapeutics annual revenue was $7 million in 2024.
Daniel Gruskin is the Chief Medical Officer of LogicBio Therapeutics.
21 people are employed at LogicBio Therapeutics.
LogicBio Therapeutics is based in Lexington, Massachusetts.
The NAICS codes for LogicBio Therapeutics are [325414, 32, 325, 32541, 3254].
The SIC codes for LogicBio Therapeutics are [28, 283].